Conv. Plasma
Nigella Sativa
Nitric Oxide
Peg.. Lambda

Home   COVID-19 treatment studies for Probiotics  COVID-19 treatment studies for Probiotics  C19 studies: Probiotics  Probiotics   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
Oropharyngeal Probiotic ENT-K12 Prevents Respiratory Tract Infections Among Frontline Medical Staff Fighting Against COVID-19: A Pilot Study
Wang et al., Front. Bioeng. Biotechnol., doi:10.3389/fbioe.2021.646184
Wang et al., Oropharyngeal Probiotic ENT-K12 Prevents Respiratory Tract Infections Among Frontline Medical Staff Fighting.., Front. Bioeng. Biotechnol., doi:10.3389/fbioe.2021.646184
Jun 2021   Source   PDF  
  All Studies   Meta
Prophylaxis RCT in China with 98 healthcare workes in close contact with COVID-19 patients treated with Bactoblis oropharyngeal probiotic containing S. thermophilus ENT-K12, and 95 control patients, showing lower incidence of respiratory infections with treatment (none were confirmed COVID-19, details of testing are not provided).
The immune effects of probiotics are strain-specific.
Wang et al., 24 Jun 2021, peer-reviewed, 13 authors.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperProbioticsAll
Abstract: ORIGINAL RESEARCH published: 24 June 2021 doi: 10.3389/fbioe.2021.646184 Oropharyngeal Probiotic ENT-K12 Prevents Respiratory Tract Infections Among Frontline Medical Staff Fighting Against COVID-19: A Pilot Study Edited by: Stephen Allen Morse, Centers for Disease Control and Prevention (CDC), United States Reviewed by: Dorothee Von Laer, Innsbruck Medical University, Austria Sumit Ghosh, The Research Institute at Nationwide Children’s Hospital, United States *Correspondence: Qiang Wang Qingming Wu Baoli Zhu Junbo Xia † These authors have contributed equally to this work and share first authorship Specialty section: This article was submitted to Biosafety and Biosecurity, a section of the journal Frontiers in Bioengineering and Biotechnology Received: 04 January 2021 Accepted: 11 May 2021 Published: 24 June 2021 Citation: Wang Q, Lin X, Xiang X, Liu W, Fang Y, Chen H, Tang F, Guo H, Chen D, Hu X, Wu Q, Zhu B and Xia J (2021) Oropharyngeal Probiotic ENT-K12 Prevents Respiratory Tract Infections Among Frontline Medical Staff Fighting Against COVID-19: A Pilot Study. Front. Bioeng. Biotechnol. 9:646184. doi: 10.3389/fbioe.2021.646184 Qiang Wang 1* † , Xuan Lin 2† , Xiaochen Xiang 1 , Wanxin Liu 1 , Ying Fang 2 , Haiping Chen 2 , Fang Tang 2 , Hongyan Guo 2 , Di Chen 2 , Xiafen Hu 1 , Qingming Wu 1* , Baoli Zhu 3,4,5,6* and Junbo Xia 7* 1 Institute of Infection, Immunology and Tumor Microenvironment, Hubei Province Key Laboratory of Occupational Hazard Identification and Control, Medical College, Wuhan University of Science and Technology, Wuhan, China, 2 Huarun WISCO General Hospital Affiliated to Wuhan University of Science and Technology, Wuhan, China, 3 CAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing, China, 4 Savaid Medical School, University of Chinese Academy of Sciences, Beijing, China, 5 Beijing Key Laboratory of Antimicrobial Resistance and Pathogen Genomics, Beijing, China, 6 Department of Pathogenic Biology, School of Basic Medical Sciences, Southwest Medical University, Luzhou, China, 7 Department of Pulmonary Medicine, Affiliated Hangzhou First People’s Hospital, Zhejiang University School of Medicine, Hangzhou, China Healthcare workers at the frontline are facing a substantial risk of respiratory tract infection during the COVID-19 outbreak due to an extremely stressful work schedule and public health event. A well-established first-line defense on oropharyngeal microbiome could be a promising strategy to protect individuals from respiratory tract infections including COVID-19. The most thoroughly studied oropharyngeal probiotic product which creates a stable upper respiratory tract microbiota capable of preventing upper respiratory tract infections was chosen to evaluate the safety and efficacy on reducing episodes of upper respiratory tract infections for COVID-19 healthcare workers. To our knowledge to date, this is the very first study describing the beneficial effects of oropharyngeal probiotic been administered by healthcare workers during the COVID-19 pandemic. In this randomized controlled trial, we provided the probiotics to frontline medical staff who work in the hospitals in Wuhan and had been in close contact with hospitalized COVID-19 patients for prophylactic use on a daily basis. Our finding suggests that oropharyngeal probiotic administration significantly..
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop